Eribulin mesylate in the treatment of metastatic breast cancer
Sarika Jain, Tessa CiglerDepartment of Medicine, Weill Cornell Medical College, New York, NY, USAAbstract: The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are app...
Guardado en:
Autores principales: | Jain S, Cigler T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e4b6daa81e6f4cc294aa1d0945c94463 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan P, et al.
Publicado: (2021) -
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
por: Twelves C, et al.
Publicado: (2011) -
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Tanya E. Keenan, et al.
Publicado: (2021) -
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
por: Marslin G, et al.
Publicado: (2015) -
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Shannon Puhalla, et al.
Publicado: (2008)